JNCE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2023 @ 16:00):

Stats
Today's Volume	11.60M
Average Volume	3.47M
Market Cap	98.95M
EPS	$0 ( 2024-03-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.958
ATR14	$0.0820 (4.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-03	Concentra Biosciences, Llc	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Sell	5 300 087	Common Stock
2023-05-03	Concentra Biosciences, Llc	Buy	0	Common Stock
2023-05-03	Salter-cid Luisa	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-96.49
Last 98 transactions
Buy: 1 025 987 \| Sell: 8 913 091

Volume Correlation

Long: -0.01 (neutral)

Short: -0.19 (neutral)

Signal:(59.515) Neutral

Jounce Therapeutics Inc Correlation

10 Most Positive Correlations
SVAC	0.941
BLPH	0.916
TZPSU	0.914
TZPS	0.913
ARRW	0.911
NBST	0.909
EBACU	0.908
MTSL	0.908
ARDX	0.903
KBAL	0.902

10 Most Negative Correlations
LWAC	-0.964
FRBA	-0.956
AMAL	-0.953
CCB	-0.953
CVBF	-0.95
RBB	-0.946
FBMS	-0.946
MYFW	-0.944
INDB	-0.942
CBAN	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jounce Therapeutics Inc Correlation - Currency/Commodity

0.54
( weak )

0.50
( weak )

0.00
( neutral )

-0.78
( moderate negative )

-0.59
( weak negative )

-0.25
( neutral )

Jounce Therapeutics Inc Financials

Annual	2022
Revenue:	$82.00M
Gross Profit:	$82.00M (100.00 %)
EPS:	$-0.990

Q4	2022
Revenue:	$82.00M
Gross Profit:	$82.00M (100.00 %)
EPS:	$0.990

Q3	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.600

Q2	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.